Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2) : A retrospective study

Asian Journal of Andrology

Volumn 9, Issue 2, 2007, Pages 253-258

  Raina, Rupesh ^a,b   Pahalajani, Geetu ^a   Agarwal, Ashok ^a   Zippe, Craig ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Ablation; Androgen; Antiandrogen; Localized prostate cancer; Luteinizing hormone releasing hormone agonist; Monotherapy; Prostate specific antigen

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; GONADORELIN AGONIST; LEUPRORELIN; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ABDOMINAL DISCOMFORT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE SCINTISCANNING; CANCER STAGING; CONTROLLED STUDY; DARK ADAPTATION; DIARRHEA; DIGITAL RECTAL EXAMINATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ETHNICITY; FATIGUE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLEASON SCORE; HOT FLUSH; HUMAN; LETHARGY; LIGHT ADAPTATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MASTALGIA; MONOTHERAPY; NAUSEA AND VOMITING; PATIENT COMPLIANCE; PROSTATE CANCER; PROTEIN BLOOD LEVEL; SIDE EFFECT; SMOKING HABIT;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANILIDES; FLUTAMIDE; GONADOTROPIN-RELEASING HORMONE; HUMANS; IMIDAZOLIDINES; LEUPROLIDE; MALE; NITRILES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TOSYL COMPOUNDS;

EID: 33947254587     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1111/j.1745-7262.2007.00074.x     Document Type: Article

References (20)

1. Dupont A, Gomez JL, Cusan L, Koutsilieris M, Labrie F. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 1993; 150: 908-13.
2. Labrie F, Cusan L, Gomez JL, Diamond P, Candas B. Combination of screening and preoperative endocrine therapy: The potential for an important decrease in prostate cancer mortality. J Clin Endocrinol Metab 1995; 80: 2002-13.
3. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics 1998. CA Cancer J Clin 1998; 48: 6-29.
4. Benoit RM, Naslund MJ. The socioeconomic implications of prostate-specific antigen screening. Urol Clin North Am 1997; 24: 451-8.
5. Fakas A, Schneider D, Perrotti M, Cummings KB, Ward WS. National trends in the epidemiology of prostate cancer, in 1973 to 1994: Evidence for the effectiveness of prostate-specific antigen screening. Urology 1998; 52: 444-8.
6. Gardner P, Hudson BL. Advance Report of Final Mortality Statistics, 1993. Monthly Vital Statistics Report, vol 44 (7) Suppl 29. Maryland: U. S. Department of Health and Human Services, Center for Disease Control and Prevention/National Center for Health Statistics; 1996.
7. Huggins C, Stevens RE, Hodges CV. Studies on prostatic cancer II. The effects of castration on advanced carcinoma of the prostate. Arch Surg 1941; 43: 209-23.
8. Bagshaw MA, Cox RS, Hancock SL. Control of prostate cancer with radiotherapy: Long-term results. J Urol 1994; 152: 6. LHRH agonist and antiandrogen therapy in localized prostate cancer 1781-5.
9. Hodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994; 330: 242-8.
10. Adolfsson J, Carstensen J, Lowhagen T. Deferred treatment in clinically localised prostatic carcinoma. Br J Urol 1992; 69: 183-7.
11. Chen, C, Poulin, R, Labrie F. Large Shionogi tumors lose their responsiveness to flutamide treatment. J Steroid Biochem Mol Biol 1996; 58: 489-94.
12. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long term survival among men with conservatively treated localized prostate cancer. JAMA 1995; 274: 626-31.
13. Schellhammer PF, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, et al. A controlled trial of bicalutamide versus flutamide, each in combination with lutinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer Casodex Combination Study Group. Urology 1995; 45: 745-52.
14. Chodak GW. Leutinizing hormone-releasing hormone releasing hormone agonists for treatment of avanced prostate carcinoma. Urology 1989; 33: 42-4.
15. Iversen P. Quality of life issues relating to endocrine treatment options. Eur Urol 1999; 36 (Suppl) 2: 20-6.
16. Delaere KP, Van Thillo EL. Flutamide monotherapy as primary treatment in advanced prostatic carcinoma. Semin Oncol 1991; 18: 13-8.
17. Dijkman GA, Janknegt RA, De Reijke TM, Debruyne FM. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization International Anandron Study Group. J Urol 1997; 158: 160-3.
18. Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, et al. A randomized comparison of Casodex (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998; 33: 447-56.
19. Schellhammer P, Lynch D. Are monotherapy options reasonable for T3 prostate cancer? Semin Urol Oncol 1997; 15: 207-14.
20. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000; 164: 1579-82.